This statistic shows the major biologics scheduled to lose patent protection between 2015 and 2020, by combined EU-5 and U.S. revenue, in billion euros. Adalimumab will lose its patent protection by 2018. This drug is generating over 10 billion euros of revenue annually. Biologicals which lose their patent protection are potentials for the biosimilars market.
Major biologics scheduled to lose patent protection between 2015 and 2020, by combined EU-5 and U.S. revenue (in billion euros)*
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Medicines for Europe. (September 8, 2016). Major biologics scheduled to lose patent protection between 2015 and 2020, by combined EU-5 and U.S. revenue (in billion euros)* [Graph]. In Statista. Retrieved December 22, 2024, from https://www.statista.com/statistics/699957/key-biologics-to-lose-patent-protection-by-us-and-eu5-sales/
Medicines for Europe. "Major biologics scheduled to lose patent protection between 2015 and 2020, by combined EU-5 and U.S. revenue (in billion euros)*." Chart. September 8, 2016. Statista. Accessed December 22, 2024. https://www.statista.com/statistics/699957/key-biologics-to-lose-patent-protection-by-us-and-eu5-sales/
Medicines for Europe. (2016). Major biologics scheduled to lose patent protection between 2015 and 2020, by combined EU-5 and U.S. revenue (in billion euros)*. Statista. Statista Inc.. Accessed: December 22, 2024. https://www.statista.com/statistics/699957/key-biologics-to-lose-patent-protection-by-us-and-eu5-sales/
Medicines for Europe. "Major Biologics Scheduled to Lose Patent Protection between 2015 and 2020, by Combined Eu-5 and U.S. Revenue (in Billion Euros)*." Statista, Statista Inc., 8 Sep 2016, https://www.statista.com/statistics/699957/key-biologics-to-lose-patent-protection-by-us-and-eu5-sales/
Medicines for Europe, Major biologics scheduled to lose patent protection between 2015 and 2020, by combined EU-5 and U.S. revenue (in billion euros)* Statista, https://www.statista.com/statistics/699957/key-biologics-to-lose-patent-protection-by-us-and-eu5-sales/ (last visited December 22, 2024)
Major biologics scheduled to lose patent protection between 2015 and 2020, by combined EU-5 and U.S. revenue (in billion euros)* [Graph], Medicines for Europe, September 8, 2016. [Online]. Available: https://www.statista.com/statistics/699957/key-biologics-to-lose-patent-protection-by-us-and-eu5-sales/
